Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name (Descending) Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
25021-0467-05 25021-0467 Octreotide acetate Octreotide Acetate 1000.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 15, 2023 In Use
68462-0896-10 68462-0896 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Aug. 9, 2023 In Use
68462-0897-10 68462-0897 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Aug. 9, 2023 In Use
63323-0376-01 63323-0376 OCTREOTIDE ACETATE Octreotide 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous March 14, 2006 In Use
63323-0376-04 63323-0376 OCTREOTIDE ACETATE Octreotide 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous March 14, 2006 In Use
63323-0377-01 63323-0377 OCTREOTIDE ACETATE Octreotide 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous March 14, 2006 In Use
63323-0377-04 63323-0377 OCTREOTIDE ACETATE Octreotide 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous March 14, 2006 In Use
63323-0378-05 63323-0378 OCTREOTIDE ACETATE Octreotide 200.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous March 14, 2006 In Use
63323-0379-05 63323-0379 OCTREOTIDE ACETATE Octreotide 1000.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous March 14, 2006 In Use
63323-0365-01 63323-0365 OCTREOTIDE ACETATE Octreotide 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous March 14, 2006 June 30, 2017 No Longer Used
63323-0365-04 63323-0365 OCTREOTIDE ACETATE Octreotide 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous March 14, 2006 June 30, 2017 No Longer Used
16729-0332-03 16729-0332 OXALIPLATIN OXALIPLATIN 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 17, 2018 In Use
16729-0332-05 16729-0332 OXALIPLATIN OXALIPLATIN 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 17, 2018 In Use
72187-0101-03 72187-0101 Elacestrant ORSERDU 86.0 mg/1 Hormonal Therapy Estrogen Receptor Antagonist ERα Oral Jan. 27, 2023 In Use
72187-0102-03 72187-0102 Elacestrant ORSERDU 345.0 mg/1 Hormonal Therapy Estrogen Receptor Antagonist ERα Oral Jan. 27, 2023 In Use
00003-7125-11 00003-7125 nivolumab and relatlimab-rmbw OPDUALAG 12.0 mg/mL, 4.0 mg/mL Immunotherapy Checkpoint Inhibitor, Monoclonal Antibody PD-1, LAG3 Intravenous March 18, 2022 In Use
00003-3756-14 00003-3756 nivolumab OPDIVO 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Aug. 30, 2021 In Use
00003-3734-13 00003-3734 Nivolumab OPDIVO 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Dec. 8, 2017 In Use
59572-0730-07 59572-0730 azacitidine ONUREG 200.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec. 18, 2020 In Use
59572-0730-14 59572-0730 azacitidine ONUREG 200.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2020 In Use
59572-0740-07 59572-0740 azacitidine ONUREG 300.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec. 18, 2020 In Use
59572-0740-14 59572-0740 azacitidine ONUREG 300.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2020 In Use
35356-0679-10 35356-0679 ONDANSETRON HYDROCHLORIDE ONDANSETRON HYDROCHLORIDE 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 June 30, 2019 In Use
35356-0679-30 35356-0679 ONDANSETRON HYDROCHLORIDE ONDANSETRON HYDROCHLORIDE 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 June 30, 2019 In Use
51655-0800-04 51655-0800 ONDANSETRON HYDROCHLORIDE ONDANSETRON HYDROCHLORIDE 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 30, 2014 In Use
64679-0726-01 64679-0726 ondansetron hydrochloride ONDANSETRON HYDROCHLORIDE 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Dec. 27, 2006 In Use
64679-0727-01 64679-0727 ondansetron hydrochloride ONDANSETRON HYDROCHLORIDE 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Dec. 27, 2006 In Use
67457-0769-02 67457-0769 ONDANSETRON HYDROCHLORIDE ONDANSETRON HYDROCHLORIDE 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Dec. 31, 2017 In Use
51662-1539-01 51662-1539 ONDANSETRON ONDANSETRON 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 6, 2021 In Use
00404-9930-02 00404-9930 ONDANSETRON ONDANSETRON 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Jan. 13, 2022 In Use
51662-1246-04 51662-1246 ONDANSETRON ONDANSETRON 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov. 19, 2018 In Use
76045-0216-20 76045-0216 ONDANSETRON HYDROCHLORIDE ONDANSETRON 4.0 mg/2mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous May 31, 2022 In Use
51662-1245-01 51662-1245 ONDANSETRON ONDANSETRON 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Sept. 23, 2018 In Use
51662-1245-03 51662-1245 ONDANSETRON ONDANSETRON 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Sept. 23, 2018 In Use
52584-0069-00 52584-0069 ONDANSETRON ONDANSETRON 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous July 3, 2018 Nov. 30, 2023 No Longer Used
73441-0800-04 73441-0800 omidubicel-onlv OMISIRGE Ancillary Therapy Immunostimulant Stem cell mobilizer Intravenous May 1, 2023 In Use
82448-0050-18 82448-0050 Nirogacestat OGSIVEO 50.0 mg/1 Ancillary Therapy Miscellaneous Agent Ɣ Secretase Inhibitor Oral Nov. 27, 2023 In Use
67457-0847-44 67457-0847 Trastuzumab OGIVRI 420.0 mg/ 20 mL Immunotherapy Monoclonal Antibody HER2 Intravenous Nov. 29, 2019 April 30, 2027 In Use
67457-0991-15 67457-0991 Trastuzumab OGIVRI 150.0 mg/7.4mL Immunotherapy Monoclonal Antibody HER2 Intravenous Nov. 29, 2019 Feb. 28, 2027 In Use
83257-0001-11 83257-0001 Trastuzumab-dkst OGIVRI 150.0 mg/7.4mL Immunotherapy Monoclonal Antibody HER2 Intravenous Oct. 1, 2023 In Use
83257-0003-01 83257-0003 Trastuzumab-dkst OGIVRI 420.0 mg/20mL Immunotherapy Monoclonal Antibody HER2 Intravenous Oct. 1, 2023 In Use
83257-0004-12 83257-0004 Trastuzumab-dkst OGIVRI Immunotherapy Monoclonal Antibody HER2 Oct. 1, 2023 In Use
76135-0009-01 76135-0009 OCTREOTIDE ACETATE OCTREOTIDE ACETATE 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Feb. 1, 2019 In Use
76135-0010-01 76135-0010 OCTREOTIDE ACETATE OCTREOTIDE ACETATE 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Feb. 1, 2019 In Use
76135-0011-01 76135-0011 OCTREOTIDE ACETATE OCTREOTIDE ACETATE 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Feb. 1, 2019 In Use
23155-0687-41 23155-0687 OCTREOTIDE ACETATE OCTREOTIDE ACETATE 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Sept. 3, 2019 In Use
23155-0688-41 23155-0688 OCTREOTIDE ACETATE OCTREOTIDE ACETATE 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Sept. 3, 2019 In Use
23155-0689-41 23155-0689 OCTREOTIDE ACETATE OCTREOTIDE ACETATE 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Sept. 3, 2019 In Use
50419-0395-01 50419-0395 Darolutamide Nubeqa 300.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral July 31, 2019 In Use
50419-0395-72 50419-0395 Darolutamide Nubeqa 300.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral March 3, 2021 In Use

Found 10,000 results in 12 milliseconds — Export these results